-
Je něco špatně v tomto záznamu ?
Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]
JC. Fernandez-Checa, P. Bagnaninchi, H. Ye, P. Sancho-Bru, JM. Falcon-Perez, F. Royo, C. Garcia-Ruiz, O. Konu, J. Miranda, O. Lunov, A. Dejneka, A. Elfick, A. McDonald, GJ. Sullivan, GP. Aithal, MI. Lucena, RJ. Andrade, B. Fromenty, M....
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, přehledy
Grantová podpora
MR/K017047/1
Medical Research Council - United Kingdom
MR/R015635/1
Medical Research Council - United Kingdom
BB/L023687/1
Biotechnology and Biological Sciences Research Council - United Kingdom
P50 AA011999
NIAAA NIH HHS - United States
- MeSH
- játra účinky léků MeSH
- konsensus * MeSH
- lékové postižení jater etiologie patofyziologie MeSH
- lidé MeSH
- paracetamol škodlivé účinky MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Research Support, N.I.H., Extramural MeSH
- Geografické názvy
- Evropa MeSH
Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.
Cell Death and Proliferation Institute of Biomedical Research of Barcelona Spain
Department of Molecular Biology and Genetics Faculty of Science Bilkent University Ankara Turkey
Department of Pediatric Research Oslo University Hosptial Oslo Norway
Exosomes Laboratory Center for Cooperative Research in Biosciences Derio Bizkaia 48160 Spain
Health Research Institute Gregorio Marañón 28007 Madrid Spain
IKERBASQUE Basque Foundation for Science Bilbao Bizkaia 48015 Spain
INSERM Univ Rennes INRAE Institut NUMECAN UMR_A 1341 UMR_S 1241 F 35000 Rennes France
Institute for Bioengineering School of Engineering The University of Edinburgh Edinburgh EH8 3DW UK
Instituto Investigaciones Biomédicas August Pi i Sunyer Universitat de Barcelona Spain
Interdisciplinary Neuroscience Program Bilkent University Ankara Turkey
Liver Unit Hospital Clínic Barcelona Spain
UNAM Institute of Materials Science and Nanotechnology Bilkent University Ankara Turkey
University of Oslo and the Oslo University Hospital Oslo Norway
USC Research Center for ALPD Keck School of Medicine Los Angeles United States CA 90033
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012152
- 003
- CZ-PrNML
- 005
- 20220506130533.0
- 007
- ta
- 008
- 220425s2021 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jhep.2021.06.021 $2 doi
- 035 __
- $a (PubMed)34171436
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Fernandez-Checa, Jose C $u Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), Spain; Liver Unit, Hospital Clínic, Barcelona, Spain; Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; USC Research Center for ALPD, Keck School of Medicine, Los Angeles, United States, CA 90033. Electronic address: checa229@yahoo.com
- 245 10
- $a Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET] / $c JC. Fernandez-Checa, P. Bagnaninchi, H. Ye, P. Sancho-Bru, JM. Falcon-Perez, F. Royo, C. Garcia-Ruiz, O. Konu, J. Miranda, O. Lunov, A. Dejneka, A. Elfick, A. McDonald, GJ. Sullivan, GP. Aithal, MI. Lucena, RJ. Andrade, B. Fromenty, M. Kranendonk, FJ. Cubero, LJ. Nelson
- 520 9_
- $a Drug-induced liver injury (DILI) is a major cause of acute liver failure (ALF) and one of the leading indications for liver transplantation in Western societies. Given the wide use of both prescribed and over the counter drugs, DILI has become a major health issue for which there is a pressing need to find novel and effective therapies. Although significant progress has been made in understanding the molecular mechanisms underlying DILI, our incomplete knowledge of its pathogenesis and inability to predict DILI is largely due to both discordance between human and animal DILI in preclinical drug development and a lack of models that faithfully recapitulate complex pathophysiological features of human DILI. This is exemplified by the hepatotoxicity of acetaminophen (APAP) overdose, a major cause of ALF because of its extensive worldwide use as an analgesic. Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.
- 650 _2
- $a paracetamol $x škodlivé účinky $7 D000082
- 650 _2
- $a lékové postižení jater $x etiologie $x patofyziologie $7 D056486
- 650 12
- $a konsensus $7 D032921
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a játra $x účinky léků $7 D008099
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bagnaninchi, Pierre $u Center for Regenerative Medicine, Institute for Regenerative and Repair, The University of Edinburgh, Edinburgh, UK, EH16 4UU; School of Engineering, Institute for Bioengineering, The University of Edinburgh, Faraday Building, Colin Maclaurin Road, EH9 3 DW, Scotland, UK
- 700 1_
- $a Ye, Hui $u Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, 28040 Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- 700 1_
- $a Sancho-Bru, Pau $u Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain
- 700 1_
- $a Falcon-Perez, Juan M $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, 48160, Spain; IKERBASQUE, Basque Foundation for Science, Bilbao, Bizkaia, 48015, Spain
- 700 1_
- $a Royo, Felix $u Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, 48160, Spain
- 700 1_
- $a Garcia-Ruiz, Carmen $u Cell Death and Proliferation, Institute of Biomedical Research of Barcelona (IIBB), Consejo Superior Investigaciones Científicas (CSIC), Spain; Liver Unit, Hospital Clínic, Barcelona, Spain; Instituto Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; USC Research Center for ALPD, Keck School of Medicine, Los Angeles, United States, CA 90033
- 700 1_
- $a Konu, Ozlen $u Department of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Turkey; Interdisciplinary Neuroscience Program, Bilkent University, Ankara, Turkey; UNAM-Institute of Materials Science and Nanotechnology, Bilkent University, Ankara, Turkey
- 700 1_
- $a Miranda, Joana $u Research Institute for iMedicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal
- 700 1_
- $a Lunov, Oleg $u Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Dejneka, Alexandr $u Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, Prague, Czech Republic
- 700 1_
- $a Elfick, Alistair $u Institute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh EH8 3DW, UK
- 700 1_
- $a McDonald, Alison $u Institute for Bioengineering, School of Engineering, The University of Edinburgh, Edinburgh EH8 3DW, UK
- 700 1_
- $a Sullivan, Gareth J $u University of Oslo and the Oslo University Hospital, Oslo, Norway; Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; Department of Pediatric Research, Oslo University Hosptial, Oslo, Norway
- 700 1_
- $a Aithal, Guruprasad P $u National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospital NHS Trust and University of Nottingham, Nottingham, UK
- 700 1_
- $a Lucena, M Isabel $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Servicio de Farmacología Clínica, Instituto de Investigación Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, UICEC SCReN, Universidad de Málaga, Málaga, Spain
- 700 1_
- $a Andrade, Raul J $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Unidad de Gestión Clínica de Enfermedades Digestivas, Instituto de Investigación, Biomédica de Málaga-IBIMA, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Malaga, Spain
- 700 1_
- $a Fromenty, Bernard $u INSERM, Univ Rennes, INRAE, Institut NUMECAN (Nutrition Metabolisms and Cancer) UMR_A 1341, UMR_S 1241, F-35000 Rennes, France
- 700 1_
- $a Kranendonk, Michel $u Center for Toxicogenomics and Human Health (ToxOmics), Genetics, Oncology and Human Toxicology, NOVA Medical School, Faculty of Medical Sciences, Universidade NOVA de Lisboa, Lisbon, Portugal
- 700 1_
- $a Cubero, Francisco Javier $u Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, 28029, Spain; Department of Immunology, Ophthalmology & ENT, Complutense University School of Medicine, 28040 Madrid, Spain; Health Research Institute Gregorio Marañón (IiSGM), 28007 Madrid, Spain
- 700 1_
- $a Nelson, Leonard J $u Center for Regenerative Medicine, Institute for Regenerative and Repair, The University of Edinburgh, Edinburgh, UK, EH16 4UU; School of Engineering, Institute for Bioengineering, The University of Edinburgh, Faraday Building, Colin Maclaurin Road, EH9 3 DW, Scotland, UK; Institute of Biological Chemistry, Biophysics and Bioengineering (IB3), School of Engineering and Physical Sciences (EPS), Heriot-Watt University, Edinburgh EH12 2AS, Scotland, UK. Electronic address: l.nelson@ed.ac.uk
- 773 0_
- $w MED00010017 $t Journal of hepatology $x 1600-0641 $g Roč. 75, č. 4 (2021), s. 935-959
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34171436 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130525 $b ABA008
- 999 __
- $a ok $b bmc $g 1789655 $s 1163353
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 75 $c 4 $d 935-959 $e 20210624 $i 1600-0641 $m Journal of hepatology $n J Hepatol $x MED00010017
- GRA __
- $a MR/K017047/1 $p Medical Research Council $2 United Kingdom
- GRA __
- $a MR/R015635/1 $p Medical Research Council $2 United Kingdom
- GRA __
- $a BB/L023687/1 $p Biotechnology and Biological Sciences Research Council $2 United Kingdom
- GRA __
- $a P50 AA011999 $p NIAAA NIH HHS $2 United States
- LZP __
- $a Pubmed-20220425